Under the acquisition, a subsidiary of Catalent will submit a tender offer of $11.50 per Juniper share. At the end of the offer, Catalent said it will complete the deal by acquiring the remainder of Juniper shares at the same price through a merger with a newly formed wholly-owned subsidiary of Calalent.
The acquisition of Juniper, Catalent said, will expand its offerings in the U.S. and Europe and will complement its global clinical and commercial supply network.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” commented Jonathan Arnold, President of Catalent Oral Drug Delivery. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
Catalent said it will continue to support Juniper’s progesterone gel franchise marketed by Merck KGaA outside of the U.S.
The acquisition is expected to close in the first quarter of Catalent’s 2019 fiscal year, which began July 1.